COMPANY
Apothecary Pharma, LLC
Apothecary Pharma, LLC: 503B outsourcing facility, warning letter recipient for Semaglutide, Tirzepatide, as stated by public registers.
503B OUTSOURCING FACILITY
Registered with FDA as a 503B outsourcing facility (compounding at scale).
| All products | Cary, NC, registered 2024-09-07 Regulator FDA 503B facility list |
|---|
WARNING LETTER RECIPIENT
Received an FDA warning letter naming the peptide.
| Semaglutide | Compounding Pharmacy/Adulterated Drug Products, 2025-12-01 Regulator FDA warning letters |
|---|---|
| Tirzepatide | Compounding Pharmacy/Adulterated Drug Products, 2025-12-01 Regulator FDA warning letters |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.